Financial Performance Highlights

Consolidated H1FY27 Results (vs H1FY26):

  • Operating Income: ₹129.29 crore (up 16.0% from ₹111.42 crore)
  • Total Income: ₹136.26 crore (up 15.5% from ₹118.01 crore)
  • EBITDA: ₹21.28 crore (down 6.3% from ₹22.71 crore)
  • EBITDA Margin: 16.5% (vs 20.4%)
  • Adjusted EBITDA: ₹28.09 crore (up 22.9% from ₹22.85 crore)
  • Adjusted EBITDA Margin: 21.7% (vs 20.5%)
  • PAT: ₹21.00 crore (down 20.7% from ₹26.47 crore)
  • PAT Margin: 15.4% (vs 24.0%)
  • EPS: ₹6.54 (down 20.7% from ₹8.25)

Consolidated Q2FY27 Results (vs Q2FY26):

  • Operating Income: ₹58.94 crore (vs ₹57.85 crore)
  • Total Income: ₹63.35 crore (vs ₹61.42 crore)
  • EBITDA: ₹14.48 crore (down 85.9% from ₹10.58 crore)
  • EBITDA Margin: 25.0% (vs 18.2%)
  • Adjusted EBITDA: ₹7.93 crore (down 25.0% from ₹10.58 crore)
  • Adjusted EBITDA Margin: 13.5% (vs 18.2%)
  • PAT: ₹4.75 crore (down 70.8% from ₹16.26 crore)
  • PAT Margin: 7.5% (vs 26.5%)
  • EPS: ₹1.47 (down 71.0% from ₹5.07)

Note: Adjusted EBITDA = EBITDA + ESOP expense + Forex gain

Strategic Developments

Acquisition Completed:

  • Company completed acquisition of 64.26% stake in Kronox Lab Sciences Ltd
  • Appointed Mr. Suresh Kalra as Managing Director and Chief Executive Officer at Kronox
  • Q2 PAT includes expenses of ₹6.64 crore related to the Kronox acquisition

Corporate Restructuring:

  • Received Board approval for amalgamation of wholly owned subsidiary Indoborax Infrastructure Private Ltd with Indo Borax Chemicals
  • Amalgamation subject to necessary approvals from NCLT and other regulatory authorities

Management Commentary

Mr. Suresh Kalra, Managing Director & CEO, commented:

  • Q2 witnessed steady demand despite seasonal monsoon impact
  • Profitability pressure due to higher raw material costs and geopolitical uncertainties in Middle East
  • Focus on operational efficiencies, prudent cost management, and optimizing product mix
  • Strategic integration and stabilization of synergies with Kronox Lab Sciences in distribution markets and procurement ecosystem
  • Expect amalgamation to unlock operational efficiencies through resource pooling and optimal utilization
  • Amalgamation will simplify governance structures and enable more agile decision-making

Company Background

Indo Borax & Chemicals Ltd, established in 1980, is India's leading manufacturer of boron-based chemicals. The company holds Food and Drug Administration (FDA) license for manufacturing Pharma Grade Boric Acid as per Indian Pharmacopoeia. Operates modern Boric Acid, Disodium Octaborate Tetrahydrate (D.O.T.), and Borax plant in Pithampur, Madhya Pradesh. First company in India to receive BIS license for manufacturing Technical Grade Boric Acid.